What is the appropriate evaluation and management for a patient presenting with weakness in both upper and lower extremities?

Evaluation and Management of Bilateral Upper and Lower Extremity Weakness

For a patient presenting with weakness in both upper and lower extremities, immediately assess for Guillain-Barré syndrome (GBS) as the primary consideration, particularly if weakness is rapidly progressive, bilateral, and accompanied by reduced or absent reflexes—this is a neurological emergency requiring urgent treatment with intravenous immunoglobulin (0.4 g/kg daily for 5 days) or plasma exchange without waiting for confirmatory testing 1.

Initial Clinical Assessment

Focus your evaluation on these specific features to distinguish GBS from other causes:

Red Flag Features Suggesting GBS 1:

• Temporal pattern: Rapidly progressive weakness reaching maximum disability within 2 weeks (if <24 hours or >4 weeks, consider alternatives)
• Distribution: Bilateral leg and/or arm weakness (may be asymmetric but always bilateral)
• Reflexes: Decreased or absent (present in most at onset, nearly all at nadir)
• Sensory symptoms: Distal paresthesias or sensory loss
• Autonomic dysfunction: Blood pressure/heart rate instability, pupillary changes, bowel/bladder dysfunction
• Pain: Frequently present (muscular, radicular, or neuropathic)
• Preceding infection: Often within weeks before onset

Atypical GBS Presentations to Recognize 1, 2, 3:

• Severe diffuse pain or isolated cranial nerve dysfunction preceding weakness
• Proximal rather than distal weakness
• "Sharp zingers" instead of typical numbness/tingling
• Lower extremity edema with weakness
• In children <6 years: refusal to bear weight, irritability, meningism, unsteady gait

Critical Immediate Actions

Respiratory Assessment 4:

Assess respiratory function immediately to identify respiratory muscle weakness—this takes priority over waiting for confirmatory tests. Patients can progress to fatal respiratory depression.

Urgent Laboratory Testing 1:

• Complete blood count
• Glucose, electrolytes, kidney and liver function (to exclude metabolic causes)
• Creatine kinase (CK) level—if elevated, consider rhabdomyolysis 4
• Thyroid function tests 5

Confirmatory Investigations 1:

• CSF examination: Cytoalbuminologic dissociation (elevated protein with normal WBC count, typically >60 mg/dL) 3
• Nerve conduction studies and EMG: Confirm diagnosis but do not delay treatment 2
• Calculate mEGOS score on admission for prognostication 1

Differential Diagnosis Algorithm

If the presentation does NOT fit GBS criteria, systematically evaluate:

Central vs. Peripheral Localization:

• Hyperreflexia or spasticity developing: Consider spinal cord pathology (infarction, compression) 6—obtain urgent MRI spine
• Upper motor neuron signs: Suggests central process, not peripheral neuropathy
• Areflexia with distal weakness: Consider other peripheral neuropathies

Pattern-Based Differential 5:

• Proximal > distal weakness: Myopathy (check CK, thyroid, vitamin D, consider inflammatory myopathy)
• Fatigable weakness: Myasthenia gravis (even with atypical distal presentation) 7—check acetylcholine receptor antibodies
• Asymmetric multifocal pattern: Mononeuropathy multiplex 8—consider vasculitis workup

Treatment Approach

For Confirmed or Highly Suspected GBS 1:

Initiate treatment immediately without waiting for confirmatory tests:

• Intravenous immunoglobulin: 0.4 g/kg daily for 5 days (preferred in most settings)
• OR Plasma exchange: 200-250 ml/kg for 5 sessions

Both treatments are equally effective; choice depends on availability and patient factors.

Common Pitfalls to Avoid:

• Delaying treatment while waiting for CSF results or nerve conduction studies 2
• Missing atypical presentations (proximal weakness, pain-predominant, isolated cranial nerve involvement) 3
• Failing to reassess for evolving central signs (hyperreflexia, spasticity) that suggest alternative diagnosis like spinal cord infarction 6
• Dismissing as post-viral myalgias when reflexes are diminished 3
• Not monitoring for autonomic complications (SIADH is common) 3

For Non-GBS Causes:

• Myopathy: Remove offending agents, correct endocrine/metabolic abnormalities, consider corticosteroids for inflammatory myopathy 5
• Myasthenia gravis: Pyridostigmine and corticosteroids 7
• Spinal cord pathology: Neurosurgical consultation, secondary stroke prevention 6

Prognostic Considerations 1:

• Recovery can continue beyond 3 years after onset
• Recurrence is rare (2-5%)
• Poor response to treatment when diagnosis is correct is unusual and should prompt reconsideration of diagnosis 4

The key to managing bilateral extremity weakness is recognizing that GBS is a neurological emergency requiring immediate treatment initiation based on clinical diagnosis alone, while simultaneously excluding life-threatening alternatives through targeted examination for upper motor neuron signs and respiratory compromise.